{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338021","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2026-08-06T20:11:43+00:00","discovered_at":"2026-08-06T20:13:00.710960+00:00","generated_at":"2026-08-06T20:15:58.314703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cytokinetics Q2 net loss $198.8M; MYQORZO revenue $25M; ACACIA-HCM positive","bullets":["Total revenues $28.6M (Q2 2025: $66.8M) including $25.3M MYQORZO net product revenue; no license/milestone revenue in Q2 2026.","Net loss $198.8M ($1.50/share) vs $134.4M ($1.12) in Q2 2025; R&D $97.8M, SG&A $104.4M.","Cash, equivalents and investments $1.7B (up from $1.1B at Mar 31, 2026) after $760.1M net from public offering of 11.3M shares at $71.","ACACIA-HCM (nHCM) met dual primary endpoints; supplemental NDA for aficamten in nHCM expected Q4 2026.","FY 2026 GAAP combined R&D+SG&A guidance raised to $860M-$890M from $830M-$870M; over 700 prescribers, ~1,500 patients dispensed MYQORZO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338021","json":"https://secwatch.observer/filing/0001193125-26-338021.json","markdown":"https://secwatch.observer/filing/0001193125-26-338021.md","text":"https://secwatch.observer/filing/0001193125-26-338021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/0001193125-26-338021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:15:58.314703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}